BiotechTube
Paracrine

Paracrine

San Diego, United States· Est.
paracrine.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Paracrine is a San Diego-based biotech founded in 2016, developing an integrated regenerative medicine and AI platform for chronic wound care. Its FDA 510(k)-cleared Stromal Vascular Therapy (SVT) has demonstrated a 95% wound closure rate in difficult cases, supported by the AiPara Suite for prediction, monitoring, and economic modeling. The company is commercially active across multiple international markets, positioning itself as a scalable, data-driven solution in the large and underserved global wound care market. Its business model focuses on providing the therapy and platform to clinics and health systems.

Chronic Wound Care

Technology Platform

Integrated platform combining autologous Stromal Vascular Fraction (SVF) cell therapy derived from adipose tissue with the AiPara Suite, a proprietary AI/ML software for patient selection, outcome prediction, remote monitoring, and economic modeling.

Funding History

1
SeedUndisclosed

Opportunities

The large and growing global advanced wound care market, driven by diabetes and aging demographics, presents a significant opportunity.
Paracrine's low-cost, high-efficacy therapy and AI-driven platform position it to capture value by reducing far more expensive complications like amputations.
International expansion into high-need markets offers a substantial growth runway.

Risk Factors

Key risks include navigating complex and varying reimbursement landscapes across different countries, competing against established wound care products and other advanced therapies, and the operational challenge of consistently scaling a procedure-based, partner-dependent model while maintaining quality and outcomes.

Competitive Landscape

Paracrine competes in the advanced wound care market against large medical device companies (e.g., Smith & Nephew, 3M, Integra LifeSciences) offering advanced dressings and skin substitutes, as well as other cell therapy and regenerative medicine approaches. Its differentiated edge is the integration of a point-of-care autologous cell therapy with a comprehensive AI platform designed to optimize clinical and economic outcomes.

More companies in Cell & Gene Therapy →More companies in United States →